Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes.
OBJECTIVE
Genital herpes (GH) recurrences and viral shedding are more frequent in the first year after initial HSV-2 infection. The objective of this study was to provide the first evaluation of valacyclovir 1 g once daily compared to placebo in reducing viral shedding in subjects newly diagnosed with GH.


METHODS
70 subjects were randomized to receive valacyclovir 1 g daily or placebo in a crossover design for 60 days with a 7-day washout period. A daily swab of the genital/anal-rectal area was self-collected for HSV-2 detection by PCR. Subjects attended the clinic for routine study visits and GH recurrence visits. Treatment differences were assessed using a nonparametric crossover analysis.


RESULTS
52 subjects had at least one PCR measurement in both treatment periods and comprised the primary efficacy population. Valacyclovir significantly reduced HSV-2 shedding during all days compared to placebo (mean 2.9% versus 13.5% of all days (P < .01), a 78% reduction). Valacyclovir significantly reduced subclinical HSV-2 shedding during all days compared to placebo (mean 2.4% versus 11.0% of all days (P < .01), a 78% reduction). However, 79% of subjects had no GH recurrences while receiving valacyclovir compared to 52% of subjects receiving placebo (P < .01).


CONCLUSIONS
In this study, the frequency of total and subclinical HSV-2 shedding was greater than reported in earlier studies involving subjects with a history of symptomatic genital recurrences. Our study is the first to demonstrate a significant reduction in viral shedding with valacyclovir 1 g daily compared to placebo in a population of subjects newly diagnosed with HSV-2 infection.
Martens
Mark G
MG
Planned Parenthood of Arkansas, Tulsa, OK 74105, USA. mgmartens@aol.com
Fife
Kenneth H
KH
Leone
Peter A
PA
Dix
Lynn P
LP
Brennan
Clare A
CA
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000821:virology*; D018258:Herpesvirus 2, Human / Q000502:physiology*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017201:Virus Shedding / Q000187:drug effects*
D000998:Antiviral Agents; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir
JAMA. 2000 Feb 9;283(6):791-4
10683059
Sex Transm Dis. 2007 Jun;34(6):339-43
17065847
Biometrics. 1972 Jun;28(2):577-84
4556704
Mayo Clin Proc. 2006 Oct;81(10):1321-7
17036557
J Infect Dis. 2004 Oct 15;190(8):1374-81
15378428
Int J STD AIDS. 1996 Jul;7(4):229-32
8876351
Sex Transm Dis. 1999 Apr;26(4 Suppl):S2-7
10227693
Ann Intern Med. 1999 Jul 6;131(1):14-20
10391810
J Clin Microbiol. 1999 Jun;37(6):1941-7
10325351
N Engl J Med. 2004 Jan 1;350(1):11-20
14702423
N Engl J Med. 1995 Sep 21;333(12):770-5
7643884
J Clin Microbiol. 1996 Mar;34(3):657-63
8904433
Ann Intern Med. 1994 Dec 1;121(11):847-54
7978697
BMJ. 1997 Jan 11;314(7074):85-6
9006449
J Infect Dis. 2002 Oct 15;186 Suppl 1:S3-28
12353183
JAMA. 2006 Aug 23;296(8):964-73
16926356
Ann Intern Med. 1996 Nov 1;125(9):776-7
8929015
Ann Intern Med. 1992 Mar 15;116(6):433-7
1310837
Ann Intern Med. 1989 Jun 1;110(11):882-7
2541645
J Clin Invest. 1997 Mar 1;99(5):1092-7
9062368
Sex Transm Dis. 2008 Jul;35(7):668-73
18461016
MMWR Recomm Rep. 2006 Aug 4;55(RR-11):1-94
16888612